Utilizing Real World Evidence: Focus on Multiple Myeloma in Older Adults – Tweetorial #1

 

 

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc. 

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

PROGRAM OVERVIEW

Evidence has demonstrated that undertreatment of fit elderly multiple myeloma (MM) patients occurs more frequently than overtreatment. While overtreatment of frail MM patients can induce unnecessary morbidity and mortality, an appropriate assessment for frailty is key to determine whether the patient is actually frail or in fact fit. This step ensures optimal outcomes and improved health-related quality of life.

This Twitter-based tutorial activity will focus on proper assessment of older patients, different scoring systems, the role of real-world evidence (RWE), and trials that support the use of RWE.  A link to a simplified, downloadable frailty scoring tool will also be provided.

FACULTY

Robert Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
The University of Texas
MD Anderson Cancer Center
Houston, Texas

 

Release date: March 1, 2022
Expiration date: March 1, 2023
Estimated time to complete activity: 15 minutes

 

TARGET AUDIENCE

This educational activity has been designed to meet the needs of community-based hematologist/oncologists, medical oncologists, physician assistants, and nurse practitioners who treat patients with MM.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • ASSESS patients for fitness/frailty to select appropriate treatment based on individual results
  • EVALUATE patient data, including real-world data such as patient reported outcomes and assessment scores, to determine the most appropriate treatment regimens
  • IDENTIFY strategies for managing toxicities and comorbidities associated with MM in older patients
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of March 1, 2022 through March 1, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Robert Orlowski, MD, PhD
Consultant: AbbVie, Bristol Myers Squibb, GlaxoSmithKline Biologicals, Karyopharm Therapeutics, Inc., Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin Corporation, Oncopeptides AB, Regeneron Pharmaceuticals, Inc.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest